PROGRESSIVE LEUKOENCEPHALOPATHY, MULTIPLE MYELOMA
(USA) Initial information was received on 16/Jun/2015 from a nurse in the prescribers office. This information is in 
regard to a 69 year old male who, based on dispensing information provided previously by the prescriber, received 
Pomalyst 4mg oral, daily from/Feb/2015 to //2015 for the treatment of multiple myeloma.  Lot number and expiration
date were unknown. Relevant medical history and concomitant medications were not provided. 
The nurse reported that on (b) (6)  the patient passed away from progressive leukoencephalopathy and 
multiple myeloma. The nurse did not provide an assessment of the relationship of progressive 
leukoencephalopathy and multiple myeloma to Pomalyst. The company assessed the relationship of progressive 
leukoencephalopathy to Revlimid as possible and multiple myeloma as not related. Additional information will be 
requested from the prescriber.
Print Time: 13-JUN-2016 09:36 AM If a field is blank, there is no data for that field Page 21 of 457
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
This Case linked to 163-20785-12121376 (Thrombosis)(USA)
Upon internal review on 16Jul2015, corrections were made to the case.  Company causality assessment of 
progressive leukoencephalopathy to Pomalyst (not Revlimid) was possible. Past drug therapies included Thalomid 
per dispensing database at 200mg oral once daily from Feb2006 to unknown date in 2006 for multiple myeloma; 
Revlimid, per dispensing database at 25mg oral once daily from Dec2012 to Jan2015, for multiple myeloma.